Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008)

Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008)

249
Disis, Mary LUniversity of Washington
Topo2, Cathepsin D, Cyclin B, CEA, IGFBP2, NY-ESO-1, Her-2/neu, p53
Other
Proteomics
G.I. and Other Associated Cancers Research Group

The proposed study aims to validate the diagnostic value of a panel of serum antibodies for the early detection of colorectal cancer (CRC). We have developed a serum antibody based assay that shows promise in discriminating sera from CRC patients from healthy donors. We have evaluated two separate sample sets of sera that were available either commercially or were comprised of left over samples from previous studies by our group. Both sample sets showed concordance in discriminatory power. We have not been able to identify investigators with a larger, well defined sample set of early stage colon cancer sera and request assistance from the EDRN in obtaining such samples to help assess the potential diagnostic value of our autoantibody panel

To validate the diagnostic value of a panel of serum antibodies (cathepsin D, p53, cyclin B1, topoisomerase IIalpha, IGFBP2, CEA) for the early detection of colorectal cancer.
We will run ELISA blinded to case status, data along with our prediction of disease status for each sample, will be sent to EDRN-DMCC at Fred Hutchinson Cancer Research Center for statistical analysis. DMCC already has the combination role from our preliminary study. Our preliminary data suggested that at high specificity 90%, sensitivity is 57%. With n=50 in each group, we have more than 80% power to confirm this level of sensitivity against an inferior sensitivity of 37% at 90% specificity comparing CRC versus normal controls. We understand that the reference set is not powered for definitive validation but to help prioritization. We did not have the data on patients with adenoma but the performance on early-stage CRC suggests that it is possible our marker panel could detection early lesions like adenoma,
Goodell V, Lu H, Delong J, Disis ML. Antibody Immunity to a Panel of Oncogenic Proteins May Predict Presence of Colorectal Cancer and Stage of Disease. Manuscript in preparation.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.